Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

User Fee Limbo: FDA Will Not Have Access To Extra Industry Funds At FY 2013 Start

This article was originally published in The Gray Sheet

Executive Summary

The new fiscal year starts Oct. 1, but FDA will not be able to spend the full amount of fiscal year 2013 industry user fees as a result of an emergency spending bill, and Congress is not expected to fix the issue until after the election in November at the earliest.

You may also be interested in...



News In Brief

Obama signs appropriations bill giving FDA expanded user fee access. Bausch & Lomb IPO. More news.

News In Brief

Caution on robotic surgery from Ob/Gyn group. FDA gets closer to gaining access to most of fiscal 2013 user fees. More news.

Device User Fee Fix Included In House-Passed Continuing Resolution

A continuing resolution bill approved by the House March 6 includes provisions that would permit FDA full access to medical device user fees at FY 2013 levels.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT031594

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel